Exogenous endothelial cells as accelerators of hematopoietic reconstitution

J. C. Mizer, Thomas E. Ichim, Doru T. Alexandrescu, Constantin A. Dasanu, Famela Ramos, Andrew Turner, Erik J. Woods, Vladimir Bogin, Michael Murphy, David Koos, Amit N. Patel

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Despite the successes of recombinant hematopoietic-stimulatory factors at accelerating bone marrow reconstitution and shortening the neutropenic period post-transplantation, significant challenges remain such as cost, inability to reconstitute thrombocytic lineages, and lack of efficacy in conditions such as aplastic anemia. A possible means of accelerating hematopoietic reconstitution would be administration of cells capable of secreting hematopoietic growth factors. Advantages of this approach would include: a) ability to regulate secretion of cytokines based on biological need; b) long term, localized production of growth factors, alleviating need for systemic administration of factors that possess unintended adverse effects; and c) potential to actively repair the hematopoietic stem cell niche. Here we overview the field of hematopoietic growth factors, discuss previous experiences with mesenchymal stem cells (MSC) in accelerating hematopoiesis, and conclude by putting forth the rationale of utilizing exogenous endothelial cells as a novel cellular therapy for acceleration of hematopoietic recovery.

Original languageEnglish
Article number231
JournalJournal of Translational Medicine
Volume10
Issue number1
DOIs
StatePublished - Nov 21 2012

Fingerprint

Endothelial cells
Particle accelerators
Intercellular Signaling Peptides and Proteins
Endothelial Cells
Stem cells
Stem Cell Niche
Aplastic Anemia
Hematopoiesis
Hematopoietic Stem Cells
Mesenchymal Stromal Cells
Bone
Repair
Transplantation
Bone Marrow
Cytokines
Costs and Cost Analysis
Recovery
Costs
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Mizer, J. C., Ichim, T. E., Alexandrescu, D. T., Dasanu, C. A., Ramos, F., Turner, A., ... Patel, A. N. (2012). Exogenous endothelial cells as accelerators of hematopoietic reconstitution. Journal of Translational Medicine, 10(1), [231]. https://doi.org/10.1186/1479-5876-10-231

Exogenous endothelial cells as accelerators of hematopoietic reconstitution. / Mizer, J. C.; Ichim, Thomas E.; Alexandrescu, Doru T.; Dasanu, Constantin A.; Ramos, Famela; Turner, Andrew; Woods, Erik J.; Bogin, Vladimir; Murphy, Michael; Koos, David; Patel, Amit N.

In: Journal of Translational Medicine, Vol. 10, No. 1, 231, 21.11.2012.

Research output: Contribution to journalArticle

Mizer, JC, Ichim, TE, Alexandrescu, DT, Dasanu, CA, Ramos, F, Turner, A, Woods, EJ, Bogin, V, Murphy, M, Koos, D & Patel, AN 2012, 'Exogenous endothelial cells as accelerators of hematopoietic reconstitution', Journal of Translational Medicine, vol. 10, no. 1, 231. https://doi.org/10.1186/1479-5876-10-231
Mizer JC, Ichim TE, Alexandrescu DT, Dasanu CA, Ramos F, Turner A et al. Exogenous endothelial cells as accelerators of hematopoietic reconstitution. Journal of Translational Medicine. 2012 Nov 21;10(1). 231. https://doi.org/10.1186/1479-5876-10-231
Mizer, J. C. ; Ichim, Thomas E. ; Alexandrescu, Doru T. ; Dasanu, Constantin A. ; Ramos, Famela ; Turner, Andrew ; Woods, Erik J. ; Bogin, Vladimir ; Murphy, Michael ; Koos, David ; Patel, Amit N. / Exogenous endothelial cells as accelerators of hematopoietic reconstitution. In: Journal of Translational Medicine. 2012 ; Vol. 10, No. 1.
@article{d2a7b25a3abf40f1bab4e655f7620fdf,
title = "Exogenous endothelial cells as accelerators of hematopoietic reconstitution",
abstract = "Despite the successes of recombinant hematopoietic-stimulatory factors at accelerating bone marrow reconstitution and shortening the neutropenic period post-transplantation, significant challenges remain such as cost, inability to reconstitute thrombocytic lineages, and lack of efficacy in conditions such as aplastic anemia. A possible means of accelerating hematopoietic reconstitution would be administration of cells capable of secreting hematopoietic growth factors. Advantages of this approach would include: a) ability to regulate secretion of cytokines based on biological need; b) long term, localized production of growth factors, alleviating need for systemic administration of factors that possess unintended adverse effects; and c) potential to actively repair the hematopoietic stem cell niche. Here we overview the field of hematopoietic growth factors, discuss previous experiences with mesenchymal stem cells (MSC) in accelerating hematopoiesis, and conclude by putting forth the rationale of utilizing exogenous endothelial cells as a novel cellular therapy for acceleration of hematopoietic recovery.",
author = "Mizer, {J. C.} and Ichim, {Thomas E.} and Alexandrescu, {Doru T.} and Dasanu, {Constantin A.} and Famela Ramos and Andrew Turner and Woods, {Erik J.} and Vladimir Bogin and Michael Murphy and David Koos and Patel, {Amit N.}",
year = "2012",
month = "11",
day = "21",
doi = "10.1186/1479-5876-10-231",
language = "English",
volume = "10",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Exogenous endothelial cells as accelerators of hematopoietic reconstitution

AU - Mizer, J. C.

AU - Ichim, Thomas E.

AU - Alexandrescu, Doru T.

AU - Dasanu, Constantin A.

AU - Ramos, Famela

AU - Turner, Andrew

AU - Woods, Erik J.

AU - Bogin, Vladimir

AU - Murphy, Michael

AU - Koos, David

AU - Patel, Amit N.

PY - 2012/11/21

Y1 - 2012/11/21

N2 - Despite the successes of recombinant hematopoietic-stimulatory factors at accelerating bone marrow reconstitution and shortening the neutropenic period post-transplantation, significant challenges remain such as cost, inability to reconstitute thrombocytic lineages, and lack of efficacy in conditions such as aplastic anemia. A possible means of accelerating hematopoietic reconstitution would be administration of cells capable of secreting hematopoietic growth factors. Advantages of this approach would include: a) ability to regulate secretion of cytokines based on biological need; b) long term, localized production of growth factors, alleviating need for systemic administration of factors that possess unintended adverse effects; and c) potential to actively repair the hematopoietic stem cell niche. Here we overview the field of hematopoietic growth factors, discuss previous experiences with mesenchymal stem cells (MSC) in accelerating hematopoiesis, and conclude by putting forth the rationale of utilizing exogenous endothelial cells as a novel cellular therapy for acceleration of hematopoietic recovery.

AB - Despite the successes of recombinant hematopoietic-stimulatory factors at accelerating bone marrow reconstitution and shortening the neutropenic period post-transplantation, significant challenges remain such as cost, inability to reconstitute thrombocytic lineages, and lack of efficacy in conditions such as aplastic anemia. A possible means of accelerating hematopoietic reconstitution would be administration of cells capable of secreting hematopoietic growth factors. Advantages of this approach would include: a) ability to regulate secretion of cytokines based on biological need; b) long term, localized production of growth factors, alleviating need for systemic administration of factors that possess unintended adverse effects; and c) potential to actively repair the hematopoietic stem cell niche. Here we overview the field of hematopoietic growth factors, discuss previous experiences with mesenchymal stem cells (MSC) in accelerating hematopoiesis, and conclude by putting forth the rationale of utilizing exogenous endothelial cells as a novel cellular therapy for acceleration of hematopoietic recovery.

UR - http://www.scopus.com/inward/record.url?scp=84869237694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869237694&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-10-231

DO - 10.1186/1479-5876-10-231

M3 - Article

C2 - 23171397

AN - SCOPUS:84869237694

VL - 10

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 231

ER -